Related references
Note: Only part of the references are listed.Healing of non-displaced fractures produced by fatigue loading of the mouse ulna
Mario D. Martinez et al.
BONE (2010)
Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies
Andrea Giusti et al.
BONE (2010)
Unusual mid-shaft fractures during long-term bisphosphonate therapy
Clarita V. Odvina et al.
CLINICAL ENDOCRINOLOGY (2010)
Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy
Katerina Cermak et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2010)
Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture?
Joyce S. B. Koh et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side?
M. H. Edwards et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Fragility fractures of the hip and femur: incidence and patient characteristics
J. W. Nieves et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Low-Energy Femoral Fractures Associated With Long-Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series
Robert D. Bunning et al.
PM&R (2010)
Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate
Jorg Schilcher et al.
ACTA ORTHOPAEDICA (2009)
Spontaneous femoral shaft fracture after long-term alendronate
Tamir Ali et al.
AGE AND AGEING (2009)
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
Michael R. McClung et al.
BONE (2009)
Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: A case series
D. A. Glennon
BONE (2009)
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
Reina Armamento-Villareal et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy
Arkan S. Sayed-Noor et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2009)
Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates A Case Series from a Swiss University Hospital
Kuntheavy Ing-Lorenzini et al.
DRUG SAFETY (2009)
Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium
Joon Kiong Lee
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2009)
Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy
Craig M. Capeci et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2009)
Bilateral Fractures of the Femur Diaphysis in a Patient With Rheumatoid Arthritis on Long-Term Treatment With Alendronate: Clues to the Mechanism of Increased Bone Fragility
Matthijs P. Somford et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study
Bo Abrahamsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Atraumatic Bilateral Femur Fracture in Long-Term Bisphosphonate Use
Maria S. Goddard et al.
ORTHOPEDICS (2009)
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
B. A. Lenart et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
A. L. Boskey et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report
Arkan S. Sayed-Noor et al.
ACTA ORTHOPAEDICA (2008)
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
Rene Rizzoli et al.
BONE (2008)
Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment
Matthew R. Allen et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension
Jacob A. Stakkestad et al.
CLINICAL RHEUMATOLOGY (2008)
An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?
Ernest Beng Kee Kwek et al.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2008)
Severely suppressed bone turnover and atypical skeletal fragility
Maja Visekruna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Low-energy femoral shaft fractures associated with alendronate use
Andrew S. Neviaser et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2008)
More on Atypical Fractures of the Femoral Diaphysis
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate
Brett A. Lenart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Case finding for the management of osteoporosis with FRAX® -: assessment and intervention thresholds for the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
Paul D. Miller et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment
Matthew R. Allen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report
Bahtiyar Demiralp et al.
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY (2007)
Looking beyond low bone mineral density: Multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy
P. Lee et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution
S.-K. Goh et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis
Reina Armamento-Villareal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate
Erich Durchschlag et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
Matthew R. Allen et al.
BONE (2006)
Microcrack initiattion occurs more easily in vertebrae from beagles treated with alendronate than with risedronate
K Iwata et al.
BONE (2006)
Looking back: developments in our understanding of the occurrence, aetiology and prognosis of osteoporosis over the last 50 years
TW O'Neill
RHEUMATOLOGY (2005)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Severely suppressed bone turnover: A potential complication of alendronate therapy
CV Odvina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Intervention thresholds for osteoporosis in the UK
JA Kanis et al.
BONE (2005)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis
R Recker et al.
BONE (2004)
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
OH Sorensen et al.
BONE (2003)
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats
YP Cao et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
P Roschger et al.
BONE (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
DM Black et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
GY Boivin et al.
BONE (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
